Compare Stocks → Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABOSNYSE:AMAMNASDAQ:GNFT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$3.47-0.9%$3.86$1.81▼$11.31$208.48M0.08378,201 shs150,942 shsAMAMAmbrx Biopharma$28.00$27.94$6.55▼$28.15$1.77B-1.922.12 million shsN/AGNFTGenfit$3.46-4.7%$3.62$2.89▼$4.75$172.41M1.0815,652 shs3,416 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals-0.86%-6.47%-12.81%-5.71%-3.34%AMAMAmbrx Biopharma0.00%0.00%0.00%+1.49%+146.48%GNFTGenfit-4.68%-5.68%-1.70%+3.59%-7.86%Top 5 Tech Stocks to Buy for 2024 (Ad)Elon Musk just Triggered a BOOM in These Stocks Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk.Click here to sign up for our free report & newsletterMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABOSAcumen Pharmaceuticals2.5082 of 5 stars3.53.00.00.02.42.50.6AMAMAmbrx Biopharma0.0549 of 5 stars1.30.00.00.00.01.70.6GNFTGenfit0.7947 of 5 stars3.53.00.00.00.60.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals3.00Buy$12.25253.03% UpsideAMAMAmbrx Biopharma2.50Moderate Buy$24.13-13.84% DownsideGNFTGenfit3.00Buy$11.00217.92% UpsideCurrent Analyst RatingsLatest AMAM, GNFT, and ABOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.003/27/2024ABOSAcumen PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/AAMAMAmbrx Biopharma$7.40M238.95N/AN/A$3.05 per share9.18GNFTGenfit$41.31M4.17N/AN/A$1.48 per share2.34Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$52.37M-$1.09N/AN/AN/AN/A-23.40%-21.78%5/14/2024 (Estimated)AMAMAmbrx Biopharma-$78MN/A0.00N/AN/AN/AN/AN/AN/AGNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)Latest AMAM, GNFT, and ABOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023ABOSAcumen Pharmaceuticals-$0.29-$0.29N/A-$0.29N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AAMAMAmbrx BiopharmaN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.1119.0119.01AMAMAmbrx BiopharmaN/A13.2813.28GNFTGenfit0.922.942.94OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%AMAMAmbrx Biopharma77.28%GNFTGenfit2.24%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals7.50%AMAMAmbrx Biopharma0.64%GNFTGenfit4.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals3960.08 million55.57 millionOptionableAMAMAmbrx Biopharma8763.15 million62.75 millionOptionableGNFTGenfit15449.83 million47.74 millionNot OptionableAMAM, GNFT, and ABOS HeadlinesSourceHeadlineGENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documentsglobenewswire.com - April 15 at 4:10 PMGENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-Fglobenewswire.com - April 5 at 2:00 PMGenfit's (GNFT) Buy Rating Reiterated at HC Wainwrightmarketbeat.com - April 5 at 8:28 AMGENFIT S.A.: GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - April 5 at 4:56 AMGENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - April 4 at 4:10 PMEuropean Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Tradingmsn.com - April 3 at 12:51 PMGenfit S.A. (NASDAQ:GNFT) Short Interest Updatemarketbeat.com - April 2 at 10:00 AMEuropean Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Tradingmsn.com - March 27 at 1:06 PMGENFIT Announces Revenues and Cash Position as of December 31, 2023globenewswire.com - February 29 at 4:10 PMGENFIT S.A.thestreet.com - February 25 at 1:21 PMInventiva drops after adverse event in Phase 3 trial for NASH drugmsn.com - February 16 at 3:02 PMEuropean Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Tradingmsn.com - February 5 at 12:50 PMEuropean Equities Traded in the US as American Depositary Receipts Trend Lower in Monday Tradingmsn.com - January 29 at 1:31 PMGenfit Stock (NASDAQ:GNFT) Dividends: History, Yield and Datesbenzinga.com - December 21 at 3:56 PMGenfit SA ADR GNFTmorningstar.com - December 20 at 12:33 AMFDA grants priority review of Genfit-Ipsen liver disease drugmsn.com - December 7 at 7:56 AMIpsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBCmarkets.businessinsider.com - December 7 at 2:56 AMGENFIT Highlights ACLF Development Strategy at "ACLF Day" during AASLD The Liver Meeting® 2023benzinga.com - November 17 at 9:05 AMGENFIT Reports Third Quarter 2023 Financial Informationfinance.yahoo.com - November 9 at 6:14 PMOil Stocks Buoy European Equities Traded in the US as American Depositary Receipts Thursdaymsn.com - November 9 at 1:13 PMOil Stocks Burden European Equities Traded in the US as American Depositary Receipts Tuesdaymsn.com - November 7 at 12:41 PMGENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technologyfinance.yahoo.com - September 26 at 8:22 PMGENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Nowfinance.yahoo.com - September 26 at 3:22 PMGENFIT S.A.: GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - September 22 at 9:33 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcumen PharmaceuticalsNASDAQ:ABOSAcumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Ambrx BiopharmaNYSE:AMAMAmbrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.GenfitNASDAQ:GNFTGenfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.